In a Landscape of ‘Me Too’ Drug Development, What Spurs Radical Innovation?

Pharmaceutical companies are criticized for not producing more breakthrough drugs. But new research by Joshua Krieger and colleagues shows that, given a financial windfall, drug giants turn on the innovation.

HBS Working Knowledge

Comment